98%
921
2 minutes
20
The enzyme human aromatase (HA), a member of the cytochrome P450 family, catalyses in a highly specific and peculiar manner the conversion of estrogens to androgens. Thus, this enzyme is a relevant target for inhibitor design for the treatment of breast cancer and currently there are several HA inhibitors employed in clinical practice. The HA crystal structure was solved only in 2009 and, since then, several studies have been done to characterize a variety of its structural, dynamical and mechanistic properties. In the last decade, the predictive power and the accuracy of computer simulations techniques, either relying on force field or on "ab initio" description of the system, has enormously increased. This was mainly due to the development of more accurate algorithms, which allow accelerating the time-scale accessible by simulations techniques, and to the increase of computer power. Hence, computer simulations can now accurately paint an atomistic picture to the molecular mechanism of biomolecules providing also an estimate of the kinetic and thermodynamic properties of the enzyme at increasingly quantitative level. In this review, on the basis of selected examples taken from our work, we summarize current active research topics concerning HA enzyme, with a focus on computational studies. In particular, we will illustrate current results and novel hypothesis concerning the final (rate-determining) aromatization step promoted by this enzyme, on how the structural/dynamics/functional properties of HA are modulated in a membrane lipophilic environment, and finally on novel possible (allosteric) inhibition mechanisms which may modulate estrogen production in HA.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2174/1389557516666160623101129 | DOI Listing |
Front Endocrinol (Lausanne)
September 2025
Pediatric Endocrinology Department, Obesity, Endocrine and Metabolism Center, King Fahd Medical City, Riyadh, Saudi Arabia.
McCune-Albright syndrome (MAS) is a rare genetic disorder characterized by a triad of café-au-lait spots, fibrous dysplasia, and hyperfunctioning endocrinopathies, resulting from a mosaic mutation in the guanine nucleotide-binding protein (GNAS) gene. This case report presents the long-term follow-up of an eight-year-old girl diagnosed with MAS, who first presented at 22 months of age with skin pigmentation, hyperthyroidism, and precocious puberty, later developing additional features such as fibrous dysplasia and growth hormone excess. This complex presentation of MAS-featuring more than two hyperfunctioning endocrinopathies along with fibrous dysplasia-has rarely been described in the literature.
View Article and Find Full Text PDFJ Ovarian Res
September 2025
Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, 333, Taiwan.
Background: Polycystic ovary syndrome (PCOS) is a complex disorder characterized by various reproductive, metabolic, and endocrine abnormalities. Hyperandrogenism is a key feature of PCOS that significantly impacts ovarian function. However, its effects on granulosa cells (GCs) function for estrogen production in PCOS remains limited.
View Article and Find Full Text PDFESMO Open
September 2025
UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, USA.
Background: All three cyclin-dependent kinase 4/6 inhibitors (CDK4/6i; palbociclib, ribociclib, and abemaciclib) plus aromatase inhibitor (AI) significantly prolonged progression-free survival (PFS) versus placebo plus AI and achieved a similar reduction in risk of disease progression in randomized controlled trials (RCTs) evaluating first-line (1L) treatment of hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (mBC). To date, there have been no head-to-head RCT data comparing CDK4/6i, and most real-world comparative effectiveness studies were limited by small sample sizes and/or short follow-up. In this analysis, we compared real-world PFS (rwPFS) in patients with HR-positive/HER2-negative mBC receiving 1L CDK4/6i plus AI in United States routine clinical practice.
View Article and Find Full Text PDFEndokrynol Pol
September 2025
Department of Reproductive Health, Center of Postgraduate Medical Education, Warsaw, Poland.
Functional hypogonadism is a syndrome characterized by low testosterone levels and clinical features of hypogonadism without organic disease of the hypothalamus-pituitary-gonadal axis. It is most prevalent among middle-aged and older men as late-onset hypogonadism as well as in a wide range of conditions such as obesity, type 2 diabetes, opioid use, or exogenous steroid abuse. As a potentially reversible condition, lifestyle modifications are the basis of initial management of functional hypogonadism.
View Article and Find Full Text PDFJ Breast Cancer
August 2025
Department of Surgery, Jeonbuk National University Medical School, Jeonju, Korea.
Ribociclib combined with an aromatase inhibitor (AI) is widely used as first-line therapy for hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER-2)-negative metastatic breast cancer. Desmoid-type fibromatosis (DTF) is a rare, locally invasive soft-tissue tumor that accounts for only 0.2% of all breast neoplasms and can mimic malignancy upon imaging.
View Article and Find Full Text PDF